BioCentury
ARTICLE | Company News

Adcetris sales and marketing update

December 16, 2016 8:29 PM UTC

The U.K.’s NICE issued draft guidance recommending against the use of Adcetris brentuximab vedotin from Takeda to treat CD30-positive Hodgkin’s lymphoma. Specifically, the agency recommends against Adcetris’ use for patients with relapsed or refractory disease following autologous stem cell transplantation (ASCT), following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option or in patients with an increased risk of relapse or progression following ASCT. The new draft guidance is in line with preliminary draft guidance issued in August. The drug is available on the country's Cancer Drugs Fund for two of the three indications (see BioCentury, Aug. 15).

Takeda submitted new evidence, new analyses and a patient access scheme to the committee. However, the agency said there was still “substantial uncertainty” in the clinical evidence. It also estimated the incremental cost effectiveness ratio (ICER) per quality adjusted life year (QALY) gained vs. chemotherapy to be about £40,000 ($50,348) when taking the patient access scheme into account and said that Adcetris “could not be considered a cost-effective use of NHS resources.”...

BCIQ Company Profiles

Takeda Pharmaceutical Co. Ltd.